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Abstract
Antibody responses are important in the control of viral respiratory infection in the human host.
What is not clear for SARS-CoV-2 is how rapidly this response occurs, or when antibodies
with protective capability evolve. Hence, defining the events of SARS-CoV-2 seroconversion
and the time frame for the development of antibodies with protective potential may help to
explain the different clinical presentations of COVID-19. Furthermore, accurate descriptions of
seroconversion are needed to inform the best use of serological assays for diagnostic testing
and serosurveillance studies. Here, we describe the humoral responses in a cohort of hospital-
ised COVID-19 patients (n = 19) shortly following the onset of symptoms. Commercial and ‘in-
house’ serological assays were used to measure IgG antibodies against different SARS-CoV-
2 structural antigens–Spike (S) S1 sub-unit and Nucleocapsid protein (NP)–and to assess the
potential for virus neutralisation mediated specifically by inhibition of binding between the viral
attachment protein (S protein) and cognate receptor (ACE-2). Antibody response kinetics var-
ied amongst the cohort, with patients seroconverting within 1 week, between 1–2 weeks, or
after 2 weeks, following symptom onset. Anti-NP IgG responses were generally detected ear-
lier, but reached maximum levels slower, than anti-S1 IgG responses. The earliest IgG anti-
bodies produced by all patients included those that recognised the S protein receptor-binding
domain (RBD) and were capable of inhibiting binding to ACE-2. These data revealed events
and patterns of SARS-CoV-2 seroconversion that may be important predictors of the outcome
of infection and guide the delivery of clinical services in the COVID-19 response.
Introduction
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China,
in late 2019, followed by rapid global spread with coronavirus-disease-2019 (COVID-19)
declared a pandemic on 11th March 2020 [1, 2]. As of 30th October 2020, 44,592,789
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laboratory-confirmed cases and 1,175,533 deaths globally have been reported to WHO [3].
Due to the recent emergence of this virus, there exist substantial gaps in knowledge of the
interactions between SARS-CoV-2 and the human host. In particular, greater understanding
of immune responses to SARS-CoV-2 is required to reveal predictors to the clinical outcome
of infection, and to inform strategies for the management of patients and prevention of
onward transmission. Importantly, correlates of immune control will also guide the develop-
ment and assessment of candidate vaccines.
SARS-CoV-2 belongs to the Coronaviridae family of single-stranded, positive-sensed RNA
viruses, and is the seventh member that causes infection in humans [2, 4]. Four human coro-
naviruses (hCoVs)—hCoV-229E, hCoV-OC3, hCoV-NL63, and hCoV-HKU1—circulate
globally and are associated with seasonal mild respiratory infection [5–7]. Two coronaviruses
are associated with more severe infection; MERS-CoV that remains largely a zoonotic infec-
tion associated primarily with exposure to camels, and SARS-CoV that emerged in 2002,
though was eliminated in 2003 following concerted global efforts [8–10]. The clinical presenta-
tions of SARS-CoV-2 range in severity, from mild or even asymptomatic, to severe disease that
can include pneumonia, bronchitis, and acute respiratory distress syndrome (ARDS) [11].
Compared to SARS-CoV and MERS-CoV, SARS-CoV-2 has a lower case-fatality rate, yet
more efficient person-to-person transmission.
Immune responses to coronaviruses include the generation of antibodies against viral struc-
tural proteins, with nucleocapsid protein (NP) and spike glycoprotein (S) being the dominant
antigens and principal targets for SARS-CoV-2 serological assays [12, 13]. Importantly, the S
glycoprotein has a dual role as a viral attachment protein (VAP) and fusion protein, facilitating
virus binding and entry via the angiotensin-converting enzyme 2 (ACE-2) found on epithelial
cells lining the upper respiratory tract, lungs and gastric system [14–19]. Interactions with
ACE-2 are mediated by the receptor-binding domain (RBD) located in the S1 sub-unit of the S
protein, and antibodies specific for epitopes within the RBD contribute to the neutralisation of
SARS-CoV-2 [20–23]. The robust neutralising effect of these antibodies impedes virus replica-
tion and plays a vital role in reducing viral loads and subsequent clearance of infection [24].
The timescale between the onset of symptoms and production of anti-SARS-CoV-2 anti-
bodies (seroconversion) has been described to vary from person-to-person, likely influenced
by original inoculation dose and disease severity [24–27]. Prior to the production of protective
antibodies, however, virus replication may occur unchallenged, with onward transmission
more likely to occur [28, 29]. Hence, clearly defining the timescale for the development of anti-
bodies with protective potential will be critical to inform strategies for successful intervention.
We describe the humoral immune responses to SARS-CoV-2 seroconversion amongst a
cohort of hospitalised COVID-19 patients from whom serial sera had been collected early fol-
lowing diagnosis. This was achieved using a combination of commercial and ‘in-house’ sero-
logical assays targeting NP and S protein S1 sub-unit, and specifically the RBD of S protein. To
assess the RBD:ACE-2 binding inhibition potency of the detected antibodies we used a novel
commercial assay utilising a soluble RBD that binds to ACE-2 coated on plates [30]. Data from
this work was used to inform the best use of serological testing in the management of patients,
and to determine the utility of serology in the broader clinical and health protection services
for the COVID-19 response in Wales.
Materials and methods
Ethics statement
The work described was undertaken as part of an evaluation/verification of serological assays
that detect anti-SARS-CoV-2 antibodies for routine service delivery, and as such, was defined
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by the Cardiff and Vale (CAV) Health board ethics committee as ‘service development’. Ethical
approval and patient consent were not required. The authors did not participate in the collec-
tion of the serum samples. After gathering basic information, including gender, age, known
comorbidities, reported date of onset and outcome, samples were anonymised as part of a sin-
gle panel to test across multiple assays. All testing was conducted retrospectively, and the
results from this study were not used to guide the management of the study cohort patients.
COVID-19+ patient serum samples
Residual serum samples collected from laboratory confirmed (RT-PCR) COVID-19 inpatients
(March to May 2020) were obtained from the Blood Sciences department at the University
Hospital of Wales (UHW), Cardiff, prior to discard.
RBD ELISA and sVNT assay sensitivity and specificity panels
The sensitivity and specificity panels used during optimisation of the SARS-CoV-2 S protein
receptor-binding domain (RBD) ELISA included residual sera previously shown to be positive
(n = 29) or negative (n = 30) for anti-S1 IgG by the EuroImmun assay.
The specificity panel used for the surrogate virus neutralisation test (sVNT) included resid-
ual serum samples previously shown to be anti-S1 IgG negative (n = 19). To demonstrate the
lack of cross-reactivity with antibodies specific to other coronaviruses, this panel included sera
from patients with recent seasonal-hCoV infection (n = 10); these were collected at least 14
days following RT-PCR confirmation of seasonal hCoV infection. All four seasonal coronavi-
ruses were represented (NL63 n = 3, HKU1 n = 2, OC43 n = 4, 229E n = 1). In all cases, SARS-
CoV-2 was ruled out by RT-PCR.
Serological testing for IgG specific for the major SARS-CoV-2 antigens
Detection of IgG antibodies against the major SARS-CoV-2 structural protein antigens was
performed using CE-marked assays verified as suitable for diagnostic testing as part of the rou-
tine serological services offered at Wales Specialist Virology Centre (WSVC) [31].
SARS-CoV-2 nucleocapsid protein (NP) CMIA. Antibodies against the SARS-CoV-2
nucleocapsid protein (NP) were detected by the Abbott IgG chemiluminescent micro-particle
immunoassay (CMIA) on the fully automated, random-access, Abbott Architect platform
(Abbott, Maidenhead, UK). This assay displayed 90.24% sensitivity (95% CI: 75.20–97.06) and
100% specificity (95% CI: 95.20–100) during verification at WSVC.
SARS-CoV-2 spike (S) protein S1 sub-unit ELISA. Antibodies against the SARS-CoV-2
spike (S) protein S1 sub-unit were detected by the EuroImmun IgG ELISA (EuroImmun AG,
Lubeck, Germany) using the DS2 plate auto-analyser (Dynex Technologies Ltd, Worthing,
UK). This assay displayed 87.8% sensitivity (95% CI: 73.80–95.92) and 100% specificity (95%
CI: 88.43–100) during verification at WSVC.
SARS-CoV-2 S protein receptor-binding domain (RBD) ELISA
Antibodies against the SARS-CoV-2 S protein RBD were detected by an ‘in-house’ direct
ELISA based on a published method [32, 33]. Maxisorp (Nunc, Loughborough, UK) 96-well
plates were coated with RBD protein (2 μg/mL) in bicarbonate buffer (pH 9.6) at 4˚C over-
night. On the day of assay, wells were blocked with 3% (w/v) non-fat dried milk powder
(Sigma Aldrich, # 70166-500G) in phosphate-buffered saline containing 0.1% Tween 20
(PBS-T) for 1 hour (hr) at room temperature (RT). Dilutions of patient sera (1 in 50 in 1%
Milk PBS-T) were added to wells and incubated for antibody:RBD binding to occur (2 hr, RT).
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After washing with PBS-T, bound antibody was detected with secondary antibody (donkey
anti-human IgG F(ab’)2-horseradish peroxidase (HRP); #709-036-149, Jackson ImmunoRe-
search, Ely, UK; 1 hr RT), with reactions developed using O-phenylenediamine dihydrochlor-
ide (OPD, SIGMAFASTTM; Sigma-Aldrich, # P9187-50SET). Absorbance (OD 492 nm) was
measured in each well. Then mean background signal from two ‘blank’ wells was subtracted
from the sample signals reported. A cut-off of 0.7 OD was applied to distinguish negative/posi-
tive seroreactivity reported by the RBD ELISA.
SARS-CoV-2 RBD:ACE-2 binding inhibition
The RBD:ACE-2 binding inhibition potency of serum samples was investigated by a plate-
based SARS-CoV-2 surrogate virus neutralising test (sVNT) (GenScript, New Jersey, USA). In
brief, serum samples were mixed with soluble SARS-CoV-2 RBD-horse-radish peroxidase con-
jugates (sRBD-HRP) and incubated for antibody:sRBD-HRP binding to occur. Mixtures were
then added to wells coated with ACE-2, and plates were further incubated for sRBD-HRP:
ACE-2 binding to occur. Unbound sRBD-HRP was washed from the wells, and reactions
were developed with 3,3’,5,5’-tetramtheylnezdinehttps://en.wikipedia.org/wiki/3,3%27,5,5%
27-Tetramethylbenzidine (TMB). Absorbance (OD 450 nm) was measured in each well. The






An ‘in-house’ determined cut-off of 25% RBD:ACE-2 binding inhibition was applied to
sVNT assays.
Statistical analysis
Statistical analyses were performed in Prism v7 (Graphpad). Best-fit curve interpolation analy-
sis was performed by sigmoidal 4PL regression, with 95% CI determined from the mean sig-
nals. Seroconversion detection rates were analysed by Kaplan-Meier plots. For correlation
analyses, data were first checked for Gaussian distribution by D’Agostino and Pearson’s nor-
mality test, before performance of either Pearson’s parametric or Spearmans’s non-parametric
correlation test. The significance of any observed correlation was reported by two-tailed p test.
Results
Study cohort
Patients were recruited to the study cohort in a random, non-biased approach, based solely
on the availability of sequential sera spanning days 7–14 after laboratory confirmation (by
RT-PCR) of SARS-CoV-2. Initially, 21 patients were identified. Symptom onset dates (set as
day 0) were used to construct infection course timelines for each patient. However, these
details were not available for two patients who were subsequently excluded.
Demographic characteristics of the patient cohort are described in Table 1. Eleven (58%) of
the 19 of the patients were female, eight (42%) were male, and mean age was 70 years. The
majority of patients (84%) had clinically relevant co-morbidities (described in S1 Table). The
mean duration of inpatient stay was 29�5 days, with seven (37%) patients requiring admission
to the critical care unit (CCU); four of which were male (50% of all male patients) compared to
three female (~27% of all female patients). Three patients died (two males, one female) giving
an overall mortality rate of 16% amongst the patient cohort.
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Temporal development of anti-S protein S1 sub-unit and anti-nucleocapsid
protein (NP) IgG antibodies following the onset of COVID-19 symptoms
Both commercial assays used to explore anti-S1 IgG and anti-NP IgG are described as semi-
quantitative. Thus, whilst no titres are reported, antibody levels could be inferred by the degree
of reactivity observed (reported as ratios of sample/calibrator read-outs). This was exploited to
determine the temporal development of antibody responses against the respective antigens.
Anti-S1 IgG seroconversion was observed for 17/19 patients, though occurring with notice-
ably variable kinetics (Fig 1A). For four patients, measurable anti-S1 IgG developed within 7
days post symptom onset (pso), whilst for seven patients it clearly occurred between 7–14
days. Strikingly, the anti-S1 IgG response in patient #1 that became measurable between days
7–14 pso did not progress in the same way as seen for all other patients. For patient #15, mea-
surable anti-S1 IgG developed between days 6–10 pso. It was impossible to determine when
this seroconversion occurred in five of the patients, due to sera being collected later relative to
symptom onset dates and seroreactivity in the very first samples. No anti-S1 IgG response was
observed for patients #7 or #19. Best-fit curves (Fig 1B) and heat-maps (Fig 1C) illustrate the
different anti-S1 IgG evolution kinetics amongst the cohort.













Patient 1 M 78 Y 50 N N
Patient 2 M 72 Y 17 N N
Patient 3 M 68 Y 20 Y Y
Patient 4 F 65 Y 30 Y N
Patient 5 M 65 Y 41 N N
Patient 6 F 62 Y 19 Y N
Patient 7 F 86 Y 65 N N
Patient 8 M 59 Y 26 Y Y
Patient 9 M 32 N 25 Y N
Patient 10 F 52 Y 35 Y Y
Patient 11 M 34 Y 17 Y N
Patient 12 F 78 Y 36 N N
Patient 13 F 86 N 27 N N
Patient 14 F 91 Y 25 N N
Patient 15 F 88 Y 57 N N
Patient 16 F 75 Y 20 N N
Patient 17 F 93 Y 16 N N
Patient 18 M 78 Y 24 N N
Patient 19 F 72 Y 11 N N
Summary
n(%)d mean(med)e n(%)d mean(mede) n(%)d n(%)d
8(42)/11(58) 70(72) 3(16)/16(84) 29.5 (25) 7(37)/12(63) 3(16)/16(84)
aM = male, F = female
bY = yes, N = no
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Fig 1. Temporal emergence of anti-S1 and anti-NP IgG amongst the cohort members. Serum samples collected
from the cohort members over time were analysed for IgG against the major SARS-CoV-2 antigens. (A) Individual
time course data for anti-S1 IgG emergence, and (B) best-fit curves for anti-S1 IgG responses occurring after< 7 days
or between 7–14 days pso. Cut-offs for negative (ratio 0.8) and positive (ratio 1.1) seroreactivity in the EuroImmun
assay are depicted by solid red line and dashed red line, respectively. (C) Data from A presented as a heat-map. (D—F)
As in A-C, but for anti-NP IgG emergence. The cut-off (ratio 1.4) for negative/positive seroreactivity in the Abbott
assay depicted in solid red line. Patient #1 was considered an outlier and was therefore excluded from all best-fit curve
analyses. In B and E—dashed trend lines indicate 95% CI ranges; and r2 values describe tightness of fit. In C and E—‘?’
indicates undetermined seroconversion time frame. Kaplan-Meier curves comparing the seroconversion detection by
the EuroImmun and Abbott assays amongst (G) the seroconverted, (H) those where seroconversion was observed, and
(I) all cohort members combined.
https://doi.org/10.1371/journal.pone.0245382.g001
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Similar patterns were observed for anti-NP IgG seroconversion (Fig 1D). Patients with
rapid anti-S1 IgG responses each developed measurable anti-NP IgG within 7 days pso. Patient
#1 also seroconverted to anti-NP IgG within 7 days (earlier than anti-S1 IgG), but this response
too demonstrated stunted progression. The majority of the remaining patients with later anti-
S IgG responses also produced anti-NP IgG slightly earlier, yet still first detectable after 7 days.
In contrast, anti-NP IgG was detected later compared to anti-S IgG for patient #13. Interest-
ingly, in seven patients, including all four rapid seroconverts, anti-NP IgG levels decreased as
infection time courses progressed. Of note, whilst no anti-S1 IgG response was seen for patient
#7, anti-NP IgG was detected late into the infection time course. No anti-NP IgG seroconver-
sion was observed for patient #19. Best-fit curves (Fig 1E) and heat-maps (Fig 1F) illustrate the
different anti-NP IgG kinetics.
In patients with earlier antibody responses, maximum anti-S1 IgG assay signals were
achieved on average by day 10 pso (Fig 1B), whilst maximum anti-NP IgG signals were
achieved by day 16 (Fig E). In patients with delayed responses, anti-S1 IgG became detectable
on average around day 11 pso with maximum signals after day 21 (Fig 1B), whilst anti-NP IgG
became detectable around day 10 with maximal signals after day 20 (Fig 1E). Overall, serocon-
version occurred more rapidly to NP than S1, and this was most apparent in the patients with
delayed responses (Fig 1G–1I).
Evolution of anti-RBD IgG following the onset of COVID-19 symptoms
Preliminary optimisation work to determine a suitable cut-off for the RBD ELISA assay
involved exploring the signals reported for sera shown to be negative (n = 30) or positive
(n = 29) for anti-S1 IgG; this was performed over two independent runs. An appropriate cut-
off was initially determined as the mean signal from the S1 IgG negative samples + 3SD, calcu-
lated as 0.5–0.6 OD units over the repeat runs. This cut-off was further adjusted to 0.7 OD
units in favour of assay specificity (100%) over sensitivity (96.55–100%) (Fig 2A).
Under these optimised assay parameters, the anti-RBD IgG responses amongst the cohort
closely matched the previously seen anti-S1 IgG responses (Fig 2B). The patients who devel-
oped measurable anti-S1 IgG within 7 days pso demonstrated equally rapid anti-RBD IgG
kinetics, whilst for the majority of patients with anti-S1 IgG first measurable after day 7, this
was also mirrored by equally delayed anti-RBD IgG kinetics. Noteworthy, anti-RBD IgG was
detectable earlier (<7 days pso) in patients #1 and #15 compared to anti-S1 IgG (> 7 days).
Furthermore, the anti-RBD-IgG response in patient #1 evolved slowly, similarly to anti-S1 IgG
and anti-NP IgG. Patient #18 also had an earlier anti-RBD IgG response compared to anti-S1
IgG, though still detectable only after 7 days. Only patient #19 developed no measurable anti-
RBD IgG, concordant with their anti-S1 IgG response.
Best-fit curve analysis (Fig 2C) and heat-maps (Fig 2D) revealed a good concordance
between anti-RBD development and the previously observed S1-IgG kinetics.
RBD:ACE-2 binding inhibition capacity of antibodies produced during
SARS-CoV-2 seroconversion
Verification of the commercial surrogate virus neutralisation test (sVNT) specificity was based
on an assessment of the background RBD:ACE-2 inhibition potency of samples previously
shown to be negative for anti-S1 IgG (n = 19). Under the manufacturer’s suggested assay cut-
off of 20% RBD:ACE-2 binding inhibition, no positive results were produced for any pan-
hCoV seronegative sample (n = 9) produced, nor nine sera from seasonal hCoV positive
patients (n = 10) (Fig 3A). However, low-level positivity was seen for one seasonal hCoV
serum sample, and specificity of the sVNT was therefore estimated at 94.74%. An ‘in-house’
PLOS ONE Development of potentially neutralising antibodies during SARS-CoV-2 seroconversion
PLOS ONE | https://doi.org/10.1371/journal.pone.0245382 January 26, 2021 7 / 18
Fig 2. Temporal emergence of anti-RBD IgG antibodies. Serum samples collected from the cohort members over
time were analysed for anti-RBD IgG by an ‘in-house’ ELISA. (A) The anti-RBD IgG ELISA was optimised by assaying
sera previously shown to be either positive (n = 29) or negative (n = 30) for anti-S1 IgG by the EuroImmun assay; each
serum was assayed in duplicate (means are depicted), and the optimisation was based on data from two separate runs.
The calculated sensitivity and specificity of the anti-RBD IgG ELISA are described in the table. (B) Individual time-
course data and (C) best-fit curves for the emergence of RBD-binding IgG occurring after< 7 days or between 7–14
days pso. In solid red line is the cut-off (0.7) for negative/positive seroreactivity. Patients #1 and #15 were considered
outliers and were therefore excluded from best-fit curve analyses. In C–dashed lines indicate 95% CI ranges; r2 values
describe tightness of fit. (D) Data from B presented as a heat-map. ‘?’ indicates undetermined seroconversion time
frame.
https://doi.org/10.1371/journal.pone.0245382.g002
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Fig 3. RBD:ACE-2 binding inhibition potency of antibodies produced over seroconversion. Serum samples
collected from the cohort members following the onset of symptoms were analysed for RBD:ACE-2 binding inhibition
potency by the GenScript surrogate Virus Neutralisation Test (sVNT). (A) An assessment of the assay specificity was
conducted using hCoV seronegative sera (n = 9) and seasonal hCoV sera (n = 10). The calculated sensitivity and
specificity of the anti-RBD IgG ELISA are described in the table. (B) Individual time-course data and (C) best-fit
curves for RBD:ACE-2 inhibition evolving after< 7 days or between 7–14 days pso. In B+C–the manufacturer’s
suggested sVNT assay cut-off (20% sRBD:ACE-2 binding inhibition relative to the negative control) is indicated by
broken red line, and the ‘in-house’ applied cut-off (25%) is indicated by solid red line. Patients #1 and #18 were
considered outliers and were therefore excluded from best-fit curve analyses. In C–dashed lines indicate 95% CI
ranges; r2 values describe tightness of fit. (D) Data from B presented as a heat-map. ‘?’ indicates undetermined
seroconversion time frame.
https://doi.org/10.1371/journal.pone.0245382.g003
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applied cut-off was determined from the mean control signal +3SD and calculated at 24.83%,
and an adjusted cut-off of 25% was applied during testing of the cohort samples in favour of
greater assay specificity (100%). Positive controls supplied with the kit demonstrated >97%
sRBD:ACE-2 binding inhibition over all runs.
Results from sVNT neutralisation assays broadly reflected the anti-RBD IgG responses
(Fig 3B). In most patients who developed detectable anti-RBD IgG within 7 days pso, this was
matched by rapid evolution of antibodies with >90% RBD:ACE-2 binding inhibition potency
within similar time. However, this same robust protective response was not seen for patient
#17 for whom RBD:ACE-2 inhibition potency peaked at ~80%, before a sharp decline
throughout the remaining sample series. The stunted anti-RBD IgG development seen for
patient #1 was matched by slowly evolving RBD:ACE-2 binding inhibition potency that did
not exceed ~85%. For patient #15 who had also demonstrated rapid anti-RBD IgG kinetics,
there was a delay in in the detection of RBD:ACE-2 inhibition. The patients with anti-RBD
IgG response first detected after >7 days pso also displayed delayed RBD:ACE-2 binding inhi-
bition evolution. Interestingly, this inhibition was detected in patients #5, #7 and #18 earlier
than anti-S1 IgG or anti-RBD IgG. Also noteworthy, the samples collected from patient #12
commenced with high blocking ability (>90%), yet this reduced rapidly in sera collected from
day 25 onwards.
On average, sRBD:ACE-2 inhibition potency in those with rapid immune responses
reached maximum measurable levels between day 9–10 pso, whilst for those with delayed
responses, RBD:ACE-2 inhibition evolved from around day 10 and reached maximal levels at
around day 19 (Fig 3C and 3D).
Correlation between the humoral response and RBD:ACE-2 binding
blocking capacity
The different seroconversion markers investigated in this study could each be significantly cor-
related with RBD:ACE-2 inhibition potency in the majority of individual patients (S1, S2 and
S3 Figs). Following exclusion of patients #12 and #17 that each displayed dramatic loss of
RBD:ACE-2 binding inhibition potency as their respective infection time-courses progressed,
the strongest association across the remaining cohort members was seen for anti-RBD IgG,
followed by anti-NP IgG and then anti-S1 IgG (Fig 4A–4C).
To explore any difference in these correlations according to response kinetics, the cohort
patients were assigned to groups based on conclusive evidence of early seroconversion (posi-
tivity for each of anti-S1 IgG, anti-NP IgG, anti-RBD IgG and RBD:ACE-2 inhibition prior to
day 7) (Fig 4D–4F), or delayed seroconversion (positivity in the same assays clearly developing
after 7 days) (Fig 4G–4I). In both the ‘early’ and ‘delayed’ humoral response groups, anti-S1
IgG was best correlated with RBD:ACE-2 inhibition. However, in the ‘early’ responder group,
anti-NP IgG levels were correlated with RBD:ACE-2 binding inhibition potency more signifi-
cantly than anti-RBD IgG levels, yet in the delayed responder group, anti-RBD IgG levels were
correlated more significantly than anti-NP IgG levels.
Discussion
COVID-19 reached pandemic level soon after the emergence of SARS-CoV-2, and currently
remains the priority healthcare challenge globally. Although incidence has reduced since the
implementation of social restrictions, future waves of infection are anticipated as these mea-
sures are inevitably eased [34]. Hence, there is an urgent need to understand immune
responses to SARS-CoV-2. The findings we describe contribute to the growing data regarding
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humoral responses to SARS-CoV-2 and provide novel insights into the protective potential of
antibodies produced during seroconversion.
The cohort patients in our study appeared to fall within distinct temporal humoral
responder categories, with very early responses seen in some, through to very late responses
Fig 4. Correlates of RBD:ACE-2 binding inhibition potency. The relationship between anti-S1 IgG, anti-NP IgG or anti-RBD IgG levels and sRBD:
ACE-2 inhibition potency was investigated by Pearson’s correlation test (when data displayed Gaussian distribution) or by Spearman’s nonparametric
correlation test (when data were not normally distributed), with the significance of any correlation reported by two-tailed p test. (A-C) Correlation
between anti-S1 IgG, anti-NP IgG and anti-RBD IgG to RBD:ACE-2 binding inhibition potency across the cohort (excluding patients 12 and 17). (D-E
and F-H) As in A-C, though describing correlates specifically for cohort members that seroconverted with 7 days pso, or after 7 days pso, respectively.
Abbreviations/symbols: r describes correlate coefficients; r2 describes the coefficient of determination (for Pearson’s correlation test only); ����
p� 0.0001.
https://doi.org/10.1371/journal.pone.0245382.g004
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seen in others. However, major limitations in this categorisation are that the different serocon-
version time frames could simply reflect inaccuracies in reported dates of symptom onset, or
differences in incubation period for each infection (estimated on average 5 days, but anywhere
between 2–14 days) [35]. Nonetheless, similar variation in COVID-19 humoral response kinet-
ics have been described elsewhere [25–27, 36]. There exist few reports describing humoral-
response kinetics during seroconversion to seasonal coronaviruses. One study, based on the
challenge of individuals with hCoV-229E, described antibody emergence on average around
day 8 post exposure and peaking at day 14 [37]. For SARS-CoV and MERS-CoV infection, IgG
seroconversion is reported anywhere between one to several weeks after symptom onset [38–
42]; similar to what was observed in our cohort.
One potential explanation for the apparent ‘early’ and ‘late’ responses in this study may be
that the assays used target IgG, whilst Long and co-workers previously described alternative
SARS-CoV-2 seroconversion dominated by IgM [26]. It is therefore feasible that ‘early’ and
‘late’ immune responses described here reflect IgG and IgM dominant seroconversion, respec-
tively. The assays that we utilised appeared mostly un-affected by cross-reactive antibodies
from seasonal hCoV infection, albeit based on a relatively small panel. Many published investi-
gations have reported only little cross-reactivity for antibodies against NP, and negligible-to-
zero cross-reactivity for the spike protein S1 sub-unit and RBD [43, 44]. However, one study
does report cross-reactivity of antibodies recognising assembled S protein trimers, though the
presence of the S protein S2 sub-unit that is more conserved amongst different coronaviruses
compared to the S1 sub-unit is thought to be responsible [45]. In light of this, it seems most
plausible that any cross-reactive antibodies may have impacted anti-NP IgG assays, but not
anti-S1 IgG, anti-RBD IgG, or RBD:ACE-2 inhibition assays. The low-level RBD:ACE-2 inhi-
bition displayed by hCoV-NL63+ serum in the sVNT is curious in this regard. However, this
serum was from a patient with acute lymphoblastic leukaemia (ALL), and it is possible that
non-specific reactivity detected was due to deranged haematological features of the donor.
Earlier detection of anti-NP IgG implies this may be the most suitable seroconversion
marker for diagnostic and serosurveillance purposes, and mirrors observations reported for
SARS-CoV-2, and also SARS-CoV [36, 46]. Aside from different analytical sensitivities of the
assays used [28], one possibility for later anti-S1 IgG detection is that the extensive glycosyla-
tion of S1 antigen may impede antibody responses. This may also explain the more sensitive
detection of anti-RBD IgG compared to anti-S1 IgG, since the RBD is less densely glycosylated
[47]. Furthermore, S1 sub-unit exists in ‘up/open’ and ‘down/closed’ conformations in the S
protein trimer incorporated into virions [48–50], and antibodies recognising epitopes in alter-
native confirmations are described [51]. Thus, the conformation of S1 sub-unit used in the
EuroImmun assay may also restrict accessibility to epitopes targeted during natural infection.
Still, the concurrent detection of anti-RBD IgG that may be protective role is a clear benefit of
anti-S1 IgG assay. Furthermore, anti-S1 IgG levels appeared more stable than anti-NP IgG,
and thus may have a broader window for detection.
The different seroconversion markers assayed could be correlated with RBD:ACE-2 inhibi-
tion potency, implying that each has potential utility as prognostic markers as our understand-
ing of SARS-CoV-2 immune control increases. Most curious is the correlation with anti-NP
IgG levels. The potent humoral antigenicity of SARS-CoV NP has previously been hypothe-
sised, with NP peptides predicted to be available for B cell activation following release from
infected cells during cellular immune responses [52]. However, the functional role of anti-NP
IgG is unclear, with any contribution to neutralisation unlikely, given that NP is contained
internally within virions. Instead, roles for anti-NP IgG by Fc-mediated mechanisms have
been speculated. Hence, correlations between anti-NP IgG and RBD:ACE-2 binding inhibition
likely reflects an indirect relationship between different humoral response elements developing
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in parallel. With this in mind, it is intriguing that the two patients in whom RBD:ACE-2 bind-
ing inhibition potency decreased also had concomitant decreases in anti-NP IgG levels. Corre-
lations between RBD:ACE-2 inhibition and anti-S1 IgG or anti-RBD IgG levels are perhaps
easier to consider, since anti-S1 IgG encompass anti-RBD IgG, a subset of which inhibit bind-
ing to ACE-2. Investigations exploring concordance between the EuroImmun IgG assay, anti-
RBD IgG ELISA, and the sVNT assay have previously been reported [53, 54]. Bond et al
reported broadly equivalent sensitivity between the EuroImmun assay (93.8%) and sVNT
(91.4%) using sera collected >14 days pso, whilst McGregor et al reported perfect concordance
with anti-RBD ELISA and sVNT positivity using sera collected > 7 days pso. Direct compari-
son to our findings is difficult, since the exact time points pso at which samples used in these
works were acquired are not available. Nevertheless, high concordance between these assays is
reported here, and any discordance observed in our studies was confined to the primary sam-
ples in any given series.
Our descriptions of SARS-CoV-2 seroconversion build on those of To and co-workers [25],
but reveal new insights into the temporal development of antibodies that could contribute to
neutralisation. The demonstration that anti-RBD IgG with neutralising potential develop early
after the onset of symptoms is encouraging, and suggests immune control may commence
soon following infection. Indeed, the early emergence of neutralising potency following symp-
tom onset has been described elsewhere [55]. However, whilst our investigations of neutralis-
ing potential focussed specifically on antibodies that inhibit RBD and ACE-2 binding, not all
neutralising antibodies will be revealed by this approach. A recently described mechanism of
SARS-CoV-2 neutralisation involves antibodies cross-linking epitopes of the S1 sub-unit
‘down/closed’ conformation, thereby locking the S-protein trimer in a prefusion state, and
ultimately preventing RBD:ACE-2 interactions [51]. The RBD fragments used in the sVNT
may be refractory to ‘prefusion locking’, hence there is obvious scope to underreport the neu-
tralisation potential of sera by the sVNT. Clearly, correlates of neutralisation in the context of
live virus will undoubtedly be more meaningful.
The focus on anti-SARS-CoV-2 neutralising antibodies (nAbs) is borne from understand-
ing of the mechanisms of immune control against other coronaviruses [56]. Two protective
activities of nAbs are suggested: i) the prevention of cell-entry to impede intra-host spread and
pathogenesis; and ii) interference in the cell-entry of shed virus to reduce inter-host transmis-
sion. Considering the protective role of nAbs, the decline in neutralising potency observed for
two of the cohort members raises concerns regarding the longevity of antibody-mediated
immunity to SARS-CoV-2. There are seemingly conflicting reports regarding the longevity of
anti-SARS-CoV-2 antibodies, with waning of IgG levels during the early convalescent phase
described for both symptomatic and asymptomatic individuals [57], compared to the preserva-
tion of neutralising antibodies for up to 3 months in mild/moderate COVID-19 patients [58].
Hence, there is a need to address this issue in longitudinal studies to predict whether SARS-





S1 Fig. Correlates of RBD:ACE-2 binding inhibition amongst cohort members demon-
strating rapid humoral responses (<7 days). The relationship between anti-S1 IgG, anti-NP
IgG or anti-RBD IgG development and sRBD:ACE-2 inhibition potency was investigated by
Pearson’s correlation test and two-tailed p test. All y-axis are % RBD:ACE-2 inhibition
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reported by the sVNT assay, whilst x-axis are ratios for EuroImmun assay and Abbott assay, or
OD readouts from the RBD IgG ELISA assay. r2 describes correlation coefficients. Abbrevia-
tions/symbols: ns = no significance; � = p� 0.05; �� = p� 0.01; ��� p� 0.001; ���� p� 0.0001.
(TIF)
S2 Fig. Correlates of RBD:ACE-2 binding inhibition amongst cohort members with
delayed humoral responses (between 7–14 days). Correlations between anti-S1 IgG, anti-NP
IgG or anti-RBD IgG development and sRBD:ACE-2 inhibition evolution was investigated by
Pearson’s correlation test and two-tailed p test. All y-axis are % RBD:ACE-2 blockage from the
sVNT assay, whilst x-axis are ratios for EuroImmun assay and Abbott assay, or OD readouts
from the RBD IgG ELISA assay. r2 describes correlation coefficients. Abbreviations/symbols:
ns = no significance; � = p� 0.05; �� = p� 0.01; ��� p� 0.001; ���� p� 0.0001.
(TIF)
S3 Fig. Correlates of RBD:ACE-2 inhibition amongst the remaining cohort members. The
relationship between anti-S1 IgG, anti-NP IgG or anti-RBD IgG development and sRBD:ACE-
2 inhibition potency was investigated by Pearson’s correlation test and two-tailed p test. All y-
axis are % RBD:ACE-2 blockage from the sVNT assay, whilst x-axis are ratios for EuroImmun
assay and Abbott assay, or OD readouts from the RBD IgG ELISA assay. r2 describes correla-
tion coefficients. Abbreviations/symbols: ns = no significance; � = p� 0.05; �� = p� 0.01; ���
p� 0.001; ���� p� 0.0001.
(TIF)
S1 Table. Documented comorbidities for the cohort members. DM—Diabetes Mellitus;
CVD—Cardiovascular Disease; PVD—Peripheral Vascular Disease; Ca–Cancer; COPD—
Chronic Obstructive Pulmonary Disease; AF—Atrial Fibrillation; HTN–Hypertension; MI—
Myocardial Infarct; HIV—Human Immunodeficiency Virus; CLL—Chronic Lymphoid Leu-
kaemia; IPF—Idiopathic Pulmonary Fibrosis; CKD—Chronic Kidney Disease. aY = yes,
N = no. bn(%)–number(percentage).
(PDF)
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